grant
Evaluation of Non-covalent Antibody Drug Complexes (ADCx) for Targeted Drug Delivery
Organization UNIVERSITY OF MICHIGAN AT ANN ARBORLocation ANN ARBOR, UNITED STATESPosted 15 Dec 2024Deadline 30 Nov 2029
NIHUS FederalResearch GrantFY2026AbbreviationsAdverse ExperienceAdverse eventAffinityAnti-ERB-2Anti-HER2/c-erbB2 Monoclonal AntibodyAnti-c-ERB-2Anti-c-erbB2 Monoclonal AntibodyAnti-erbB-2Anti-erbB2 Monoclonal AntibodyAnti-p185-HER2AntibodiesAntibody-drug conjugatesAutoimmune DiseasesBindingBinding SitesBypassCancersCharacteristicsClinical TrialsCombining SiteCommunicable DiseasesComplexDedicationsDevelopmentDevelopment and ResearchDoseDrug DeliveryDrug Delivery SystemsDrug KineticsDrug TargetingDrug TherapyDrugsERBB2ERBB2 geneEnsureEvaluationEventFailureHER -2HER-2HER2HER2 GenesHER2 Monoclonal AntibodyHER2/neuHealthHerceptinInfectious DiseasesInfectious DisorderLaboratoriesLeadLigandsMalignant NeoplasmsMalignant TumorMaximal Tolerated DoseMaximally Tolerated DoseMaximum Tolerated DoseMedicationMiceMice MammalsMoAb HER2Molecular InteractionMurineMusNEU OncogeneNEU proteinOncogene ErbB2PatientsPb elementPharmaceutical PreparationsPharmacokineticsPharmacological TreatmentPharmacotherapyR & DR&DReactive SiteResearchSeriesSiteSurfaceTKR1TechnologyTestingTherapeuticToxic effectToxicitiesTrastuzumabWithdrawalantibody engineeringautoimmune conditionautoimmune disorderautoimmunity diseasec-erb-2 Monoclonal Antibodyc-erbB-2c-erbB-2 Genesc-erbB-2 Proto-Oncogenescell typedesigndesigningdevelopmentaldrug interventiondrug treatmentdrug/agenterbB-2 Genesheavy metal Pbheavy metal leadherstatininterestmalignancyneoplasm/cancerneu Genesnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapypharmaceutical interventionpharmacokinetic modelpharmacological interventionpharmacological therapypharmacology interventionpharmacology treatmentpharmacotherapeuticsresearch and developmentrhuMAb HER2
Description preview
This project proposes the development of a non-covalent antibody-based drug delivery strategy. The strategy,
abbreviated ADCx for Antibody Drug Complex, consists of an anti-drug antibody that is bound to a drug ex vivo
and targeted to a cell type of interest through a secondary affinity ligand. ADCx is designed to bypass the linker
payload…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click